NervGen Pharma Corp. Common stock (NGEN) vs Nyxoah S.A. (NYXH)
A side-by-side comparison of NervGen Pharma Corp. Common stock and Nyxoah S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NGEN
NervGen Pharma Corp. Common stock
$1.81HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
NYXH
Nyxoah S.A.
$1.45HealthcareDelayed quote: Oct 6, 2026, 11:59 AM EDT
Total return — NGEN vs NYXH
growth of $100 · dividends reinvested · last 1yNGEN -57.6% (-57.6%/yr)NYXH -71.3% (-71.3%/yr)NGEN compounded faster over this window
NGEN NYXH
NGEN vs NYXH: by the numbers
- •NGEN is the larger company ($148M vs $145M market cap).
- •Both run net losses; NGEN's is the smaller (0.00% vs -435.70% net margin).
Metrics side by side
Valuation
| Metric | NGEN | NYXH |
|---|---|---|
| P/S ratio | N/A | 5.54 |
| P/B ratio | 12.18 | 1.53 |
Profitability
| Metric | NGEN | NYXH |
|---|---|---|
| Gross margin | 0.00% | 63.13% |
| Operating margin | 0.00% | -827.76% |
| Net margin | 0.00% | -435.70% |
| ROE | -397.38% | -120.33% |
| ROIC | -223.90% | -61.13% |
Growth (annualized)
| Metric | NGEN | NYXH |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 120.68% |
| Total return CAGR (5Y) | N/A | -45.84% |
Go deeper
Dig into the metrics
NervGen Pharma Corp. Common stock ROENyxoah ROENervGen Pharma Corp. Common stock operating marginNyxoah operating marginNervGen Pharma Corp. Common stock revenue growthNyxoah revenue growthNervGen Pharma Corp. Common stock free cash flowNyxoah free cash flow
NervGen Pharma Corp. Common stock & Nyxoah appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.